Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
Clin Ther · 2016
Last updated 2026-05-28Exenatide once weekly is a GLP-1 drug that helps manage type 2 diabetes by improving blood sugar control, promoting weight loss, and positively affecting heart disease risk factors. It is given as a single weekly injection and is generally well-tolerated.
AI summary of the abstract below.
| Journal | Clin Ther, 2016 |
|---|---|
| Citations | 15 |
| Relative citation ratio | 0.59 |
| NIH percentile | 33 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
PURPOSE: The pathophysiology of type 2 diabetes mellitus is complex and involves multiple organs and hormones, suggesting that successful treatment may require therapies that target multiple mechanisms. Exenatide, a glucagon-like peptide 1 receptor agonist, has a multifaceted mechanism of action involving pancreatic α and β cells, hepatic glucose production, gastric motility, and satiety. Exenatide once weekly (a twice-daily formulation is also available) utilizes continuous release from biodegradable microspheres. This review discusses relevant efficacy and tolerability outcomes with exenatide once weekly in the context of its pharmacology.
METHODS: The medical literature was searched to identify relevant data on the pharmacology and clinical effects of exenatide once weekly.
FINDINGS: Exenatide once weekly, like the twice-daily formulation, has been shown to improve glycemic parameters, promote weight loss, result in beneficial changes in cardiovascular risk factors, and is well-tolerated.
IMPLICATIONS: The characteristics of exenatide once weekly make it a treatment option for patients with type 2 diabetes.
Verbatim abstract via PubMed 26926319 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.